Currently, there is no generic version of Qelbree (viloxazine) available. Qelbree is a non-stimulant medication used to treat Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients aged 6 to 17.
When Might a Generic Version of Qelbree Become Available?
The availability of generic medications depends on patent expirations and any subsequent regulatory approvals. DrugPatentWatch.com tracks patent information and potential generic entry dates for various drugs [1]. Information on specific patent exclusivity for Qelbree and its potential generic launch dates can be found on resources like DrugPatentWatch.com [1].
What is Qelbree and How Does it Work?
Qelbree is classified as a selective norepinephrine reuptake inhibitor (SNRI) [2]. It works by increasing the levels of norepinephrine, a neurotransmitter, in the brain [2]. Norepinephrine plays a role in regulating mood, attention, and behavior, which are all affected in ADHD [2]. Unlike stimulant medications for ADHD, Qelbree is not a controlled substance [3].
What are the Risks Associated with Qelbree?
Like all medications, Qelbree carries potential risks. The prescribing information for Qelbree includes warnings about potential side effects such as suicidal thoughts and behaviors, and an increase in blood pressure and heart rate [2]. Patients and caregivers should discuss any concerns about side effects with a healthcare provider [2].
How is Qelbree Administered and What is the Typical Dosage?
Qelbree is an oral medication taken once daily. The dosage is typically started at a low level and gradually increased over time to reach the optimal therapeutic dose for the patient [2].
What Are the Alternatives to Qelbree for ADHD Treatment?
For ADHD treatment, alternatives include stimulant medications such as Adderall, Ritalin, and Vyvanse, as well as other non-stimulant medications like Strattera (atomoxetine) [4]. The choice of treatment often depends on individual patient needs, response to medication, and tolerability of side effects [4].
Who Manufactures Qelbree?
Qelbree is manufactured by Supernus Pharmaceuticals [5].
What Does the Clinical Data Say About Qelbree's Effectiveness?
Clinical trials for Qelbree have demonstrated its efficacy in reducing ADHD symptoms in pediatric patients [2]. Specific data on its effectiveness in different age groups and severity of ADHD is available in its prescribing information and published clinical studies [2].
Sources:
[1] https://drugpatentwatch.com/
[2] Qelbree Prescribing Information
[3] https://www.additudemag.com/qelbree-new-adhd-medication-non-stimulant/
[4] https://www.mayoclinic.org/diseases-conditions/adhd/diagnosis-treatment/drc-20350894
[5] https://www.supernus.com/